A ‘last ditch’ drug for prostate cancer sufferers is to be axed from NHS use. Jevtana gives men with advanced disease at least three extra months of life – but some have survived three or more years. The Cancer Drugs Fund plans to remove the drug from its approved list effective from March because of weak cost-effectiveness. Although it will remain available for existing patients, doctors will be unable to prescribe it for hundreds of men with the disease. A 'last ditch' drug for prostate cancer sufferers is to be axed from NHS use from March this year. The chemotherapy drug Jevtana gives men with advanced disease at least three extra months of life - but some have survived for more than three years. Cancer charities say NHS England has failed patients (file photo)
@highlight
Jetvana gives men with prostate cancer at least three months of life
@highlight
But some men given the drug have survived three or more years
@highlight
Cancer Drugs Fund plans to axe drug from its approved list from March
@highlight
They say it is not cost-effective and doesn't offer 'sufficient clinical benefit'
@highlight
Charities say the appraisal system for drugs is broken, failing patients
@highlight
40,000 men in Britain diagnosed each year, over 10,000 die from disease
Prostate cancer is the most common cancer in men in the @placeholder, with over 40,000 new cases diagnosed every year.